|
|
Anavex adds Dr. Paul Aisen to Scientific Advisory Board
Sources News Release
http://www.sources.com/Releases/NR1170.htm
Publisher: Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Date Written: 16/02/2011
Year Published: 2011
Resource Type: Article
Anavex Life Sciences Corp. (OTCBB: AVXL) has announced the appointment of Dr. Paul Aisen to the Scientific Advisory Board (SAB) as a clinical expert. The SAB works closely with the company to support development of the Anavex product pipeline
Abstract: Hoboken, NJ – February 16, 2011 -- Anavex Life Sciences Corp. (“Anavex”, AVXL.OB) today announced the appointment of Dr. Paul Aisen to the Scientific Advisory Board (SAB) as a clinical expert. The SAB works closely with the company to support development of the Anavex product pipeline, including its lead compound ANAVEX 2-73, which is being studied for Alzheimer’s disease and is scheduled to enter Phase I clinical trials shortly.
Dr. Aisen is a leading clinician and researcher in Alzheimer’s...
To read the full release go to http://www.sources.com/Releases/NR1170.htm
Topics
|
AlterLinks
c/o Sources
© 2025.
|
|
|
|
